Safe Harbor

Forward looking statements

This communication contains certain forward-looking statements, relating to the Company’s business, which can be identified by the use of forward-looking terminology such as “estimates”, “believes”, “expects”, “may”, “will” “should” “future”, “potential” or similar expressions or by general discussion of strategy, plans or intentions of the Company. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.

Such factors include, among others, the following: uncertainties related to results of our clinical trials, the uncertainty of regulatory approval and commercial uncertainty, reimbursement and drug price uncertainty, the absence of sales and marketing experience and limited manufacturing capabilities, attraction and retention of technologically skilled employees, dependence on licenses, patents and proprietary technology, dependence upon collaborators, future capital needs and the uncertainty of additional funding, risks of product liability and limitations of insurance, limitations of supplies, competition from other biopharmaceutical, chemical and pharmaceutical companies, environmental, health and safety matters, availability of licensing arrangements, currency fluctuations, adverse changes in governmental rules and fiscal policies, civil unrest, acts of God, acts of war, and other factors referenced in this communication.

Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.

This material is not intended as an offer or solicitation for the purchase or sale of shares of Heidelberg Pharma AG. This material may not be distributed within countries where it may violate applicable law.
Heidelberg Pharma – a Clinical Stage Company

**Our Company**
- 113 employees
- Headquarters in **Heidelberg** area, Germany
- Listed on Frankfurt Stock Exchange: HPHA
- Clinical stage biotech
- Complete in-house research capabilities
- Cash reach until mid-2025 (as of July 2023)

**Our Approach**
- Inhibition of RNA Polymerase II
- Targeted delivery via antibodies (**ADC technology**)
- Use **Amanitin** as toxic payload (**ATAC technology**)

**Our Mission**
- Provide new options in cancer therapy
- Overcome resistance mechanisms
- Kill dormant tumor cells
- Develop biomarker for patient stratification
## Growing Pipeline of Proprietary and Partnered Programs

<table>
<thead>
<tr>
<th>Product</th>
<th>Target</th>
<th>Indication</th>
<th>Research</th>
<th>Preclinic</th>
<th>Phase I</th>
<th>Phase II</th>
<th>Phase III</th>
<th>Partner</th>
</tr>
</thead>
<tbody>
<tr>
<td>HDP-101</td>
<td>BCMA</td>
<td>Multiple Myeloma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Huadong (China+)</td>
</tr>
<tr>
<td>HDP-102</td>
<td>CD37</td>
<td>NHL (DLBCL/CLL)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Huadong (option China+)</td>
</tr>
<tr>
<td>HDP-103</td>
<td>PSMA</td>
<td>Prostate cancer</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Huadong (China+)</td>
</tr>
<tr>
<td>HDP-104</td>
<td>GCC</td>
<td>Gastrointestinal (e.g., CRC)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Huadong (option China+)</td>
</tr>
<tr>
<td>HDP-XX</td>
<td>n/a</td>
<td>Solid &amp; hematological malignancies</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Proprietary</td>
</tr>
</tbody>
</table>

### ATAC pipeline

### ATAC partners

<table>
<thead>
<tr>
<th>Product</th>
<th>Target</th>
<th>Indication</th>
<th>Research</th>
<th>Preclinic</th>
<th>Phase I</th>
<th>Phase II</th>
<th>Phase III</th>
<th>Partner</th>
</tr>
</thead>
<tbody>
<tr>
<td>TAK-ATAC</td>
<td>n/a</td>
<td>Oncology</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Takeda</td>
</tr>
<tr>
<td>CHIOME-ATAC</td>
<td>CDCP1</td>
<td>Oncology</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Chiome</td>
</tr>
</tbody>
</table>

### Legacy assets

<table>
<thead>
<tr>
<th>Product</th>
<th>Target</th>
<th>Indication</th>
<th>Research</th>
<th>Preclinic</th>
<th>Phase I</th>
<th>Phase II</th>
<th>Phase III</th>
<th>Partner</th>
</tr>
</thead>
<tbody>
<tr>
<td>TLX250-CDx</td>
<td>CA-IX</td>
<td>Renal and urothelial carcinoma, TNBC</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Telix</td>
</tr>
<tr>
<td>TLX250</td>
<td>CA-IX</td>
<td>Renal carcinoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Telix</td>
</tr>
<tr>
<td>RHB-107</td>
<td></td>
<td>Oncology/GI, Covid-19</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>RedHill</td>
</tr>
<tr>
<td>LH011</td>
<td></td>
<td>Pancreatic</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Link Health</td>
</tr>
</tbody>
</table>
Important Events H1 2023

Clinical trial with ATAC candidate HDP-101
- Adaptations to study protocol; continuation of patient recruitment
- Initiation of additional, new study sites in Europe
- Patient from 3rd cohort continues to be dosed and shows stable disease

Technology
- New preclinical data of the ATAC technology platform presented at the AACR 2023 Annual Meeting

Corporate events
- Walter Miller appointed Chief Financial Officer
- Divestment of minority stake in Emergence leads to higher cash inflows and earnings

Partnerships
- Research and exclusive option agreement with Binghamton University related to a novel and proprietary immunostimulatory technology platform
- Partnership with Magenta terminated due to strategy change at Magenta
Proprietary ATAC Projects
Lead Program: HDP-101 in Multiple Myeloma

Multiple Myeloma (MM)

- 70,000 deaths annually
- Median survival ~47-110 months
- Characterized by the proliferation of single clone of plasma cells derived from B-cells
- BCMA (B-cell maturation antigen) overexpression and activation are associated with MM

HDP-101: Anti-BCMA-ATAC

- Targeted elimination of BCMA-containing cells with favorable preclinical toxicity profile
- Higher potency in cells with 17p deletions, which are associated with aggressive disease
- Clinical trial started in Feb 2022

Source: healthcare-in-europe.com

Source: Heidelberg Pharma
HDP-101: Phase I/IIa Study Status

Status of the Phase I dose escalation study

- Three patient cohorts (20, 30, and 60 µg/kg) completed so far, 8 patients in total
- Latest review by Safety Review Committee in March:
  - Treatment is safe and well-tolerated in these three cohorts
  - Discussion of Magenta events: no indication that they were related to the ATAC platform
    - Voluntary implementation of additional precautionary safety measures to maximize the safety of the patients
- Dose escalation to be continued with 80 µg/kg in the fourth cohort
- US and Polish centers are currently recruiting patients

Mount Sinai Hospital, New York

MD Anderson, Houston

Emory University, Atlanta

University Hospital Heidelberg
University Hospital Mainz
University Hospital Kiel
UKSH Lübeck
University Hospital Cologne
Charité Berlin
etc.

Pratia Onkologia Katowice, Katowice
Szpital Wojewodzki w Opolu, Opole
Centrum Onkologii, Lódz

National Institute of Oncology, Budapest
Semmelweis University, Budapest

Further centers in Germany as well as Poland and Hungary are being initiated
**HDP-101: Clinical Development Plan for Multiple Myeloma**

<table>
<thead>
<tr>
<th>Year</th>
<th>Events</th>
</tr>
</thead>
<tbody>
<tr>
<td>2022</td>
<td>FPI: <strong>Dose escalation</strong> in MM patients: up to 36 patients  &lt;br&gt; First clinical safety data</td>
</tr>
<tr>
<td>2023</td>
<td>RP2D: Dose for Phase IIa</td>
</tr>
<tr>
<td>2024</td>
<td>Expansion cohorts  &lt;br&gt; BCMA naïve MM Del(17p) stratified</td>
</tr>
<tr>
<td>2025</td>
<td>Additional indications / Combinations</td>
</tr>
</tbody>
</table>

Two-part, open-label, multicenter Phase I/IIa study to determine safe dose and assess preliminary efficacy.
Further ATAC Candidates: HDP-102 and HDP-103

HDP-102: anti-CD37-ATAC

- CD37 is expressed on B-cell lymphoma cells
- Specific indication of non-Hodgkin lymphoma (NHL), relevant prevalence of 17p deletion in NHL
- Publication of scientific data in the journal *Blood*
  - Strong efficacy of a CD37-ATAC on tumor cells, leading to high tumor regression
  - Possible additional indication Richter syndrome, an aggressive form of non-Hodgkin’s lymphoma
- Production of material for preclinical and clinical studies on track
- Submission of study application planned for 2024

HDP-103: anti-PSMA-ATAC

- PSMA is overexpressed in nearly all cases of prostate cancer; limited expression in normal tissue
- Target indication is Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Prevalence of 17p deletion in mCRPC is 60%
- Production of material for preclinical and clinical studies on track
- Preclinical development completed
**Poster title: Subcutaneous dosing increases the therapeutic index of Amatoxin-based ADC**

Comparison of subcutaneous versus intravenous routes of administration in preclinical models

- Subcutaneous dosing was shown to result in prolonged half-life and lower maximum serum levels
- Improved therapeutic index of HDP-103 (improved tolerability combined with consistent efficacy)
- Patent filed for use with all ATACs

**Poster title: Amanitin-based ADCs targeting Guanylyl cyclase C (GCC) as novel therapeutic modality for treatment of colorectal cancer**

Preclinical data on ATACs targeting GCC (guanylyl cyclase C)

- GCC is overexpressed in many gastrointestinal tumors, most notably in colorectal cancer (>95%) and in ~65% of esophageal, gastric, and pancreatic tumors
- High antitumor activity and inhibition of tumor growth even at low concentrations after single or multiple dose treatment
- Favorable safety profile due to the good tolerability
- New early pipeline candidate HDP-104
Financials & Outlook
## Profit and Loss H1 2023

### Operating expenses

<table>
<thead>
<tr>
<th>in € m</th>
<th>H1 2023*</th>
<th>H1 2022*</th>
<th>Change (Change)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sales revenue and other income</td>
<td>4.7</td>
<td>12.2</td>
<td>-61%</td>
</tr>
<tr>
<td>Operating expenses</td>
<td>20.7</td>
<td>18.5</td>
<td>12%</td>
</tr>
<tr>
<td>Cost of sales</td>
<td>2.9</td>
<td>3.5</td>
<td>-17%</td>
</tr>
<tr>
<td>R&amp;D costs</td>
<td>14.8</td>
<td>11.8</td>
<td>25%</td>
</tr>
<tr>
<td>Administrative costs</td>
<td>2.3</td>
<td>2.8</td>
<td>-18%</td>
</tr>
<tr>
<td>Other expenses</td>
<td>0.7</td>
<td>0.3</td>
<td>133%</td>
</tr>
<tr>
<td>Net loss for the period</td>
<td>16.0</td>
<td>8.6</td>
<td>86%</td>
</tr>
</tbody>
</table>

* Fiscal year starts 1\(^{st}\) December; first half ends 31\(^{st}\) May

- **Sales revenue** decreased in line with planning; previous year was extraordinarily high due to the license payment of Huadong
- **R&D costs** increased as a result of the clinical trial with HDP-101 and extended manufacturing costs for the ATAC projects
- **Net loss** for the period significantly higher due to substantially lower income and higher expenses
Balance Sheet and Cash as of End of May 2023

<table>
<thead>
<tr>
<th>Assets (€ m)</th>
<th>31.05.2023</th>
<th>30.11.2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-current assets</td>
<td>13.1</td>
<td>12.7</td>
</tr>
<tr>
<td>Other current assets</td>
<td>7.5</td>
<td>6.6</td>
</tr>
<tr>
<td>Cash</td>
<td>57.4</td>
<td>81.3</td>
</tr>
<tr>
<td></td>
<td><strong>78.0</strong></td>
<td><strong>100.6</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Equity and liabilities (€ m)</th>
<th>31.05.2023</th>
<th>30.11.2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>Current liabilities</td>
<td>23.5</td>
<td>66.6</td>
</tr>
<tr>
<td>Non-current liabilities</td>
<td>3.6</td>
<td>6.0</td>
</tr>
<tr>
<td>Equity</td>
<td>50.9</td>
<td>28.0</td>
</tr>
<tr>
<td></td>
<td><strong>78.0</strong></td>
<td><strong>100.6</strong></td>
</tr>
</tbody>
</table>

- **Average cash usage per month** €3.2 m (Guidance: €2.7 to €3.1 m) compared to average cash inflow of €1.2 m in H1 2022, excluding cash effects from financing activities
- **Cash** of €57.4 m below the year-end figure of €81.3 m due to ongoing operational costs and partial loan repayment
- **Cash reach is unchanged expected until mid-2025 based on current planning**
## Guidance 2023

<table>
<thead>
<tr>
<th>in € m</th>
<th>6M 2023</th>
<th>FY 2022</th>
<th>Guidance 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sales revenue and other income</td>
<td>4.7</td>
<td>19.9</td>
<td>7.0 to 10.0</td>
</tr>
<tr>
<td>Operating expenses</td>
<td>20.7</td>
<td>37.0</td>
<td>37.0 to 41.0</td>
</tr>
<tr>
<td>R&amp;D expenses</td>
<td>14.8</td>
<td>26.4</td>
<td></td>
</tr>
<tr>
<td>Operating result (EBIT)</td>
<td>(16.0)</td>
<td>(17.2)</td>
<td>(28.5) to (32.5)</td>
</tr>
<tr>
<td>Funds required for operations, capex</td>
<td>18.9</td>
<td>8.9</td>
<td>32.5 to 36.5</td>
</tr>
<tr>
<td>Funds required per month</td>
<td>3.2</td>
<td>0.7</td>
<td>2.7 to 3.1</td>
</tr>
</tbody>
</table>
Next Steps: High Priority and Focus on HDP-101 on Clinical Progress

HDP-101 (BCMA-ATAC for MM)

Phase I/IIa study in RRMM
- Patient recruitment for 4th cohort ongoing, further study centers to be initiated
- Phase I completion in early 2024 and dose finding for Phase IIa
- Start Phase IIa part in 2024

Partnership with Huadong
- Initial discussions to conduct clinical studies in China
- Preparation of clinical trial in China started

HDP-102 (CD37-ATAC for NHL)

- Completion of preclinical and toxicological studies
- Clinical trial application 2024

HDP-103 (PSMA-ATAC for prostate cancer)

- Completion of preclinical and toxicological studies
- Clinical trial application 2025

Partner projects

Telix (TLX250-CDx)
- Filing for regulatory approval with the FDA and other agencies
- Planned approval in ccRCC and launch in 2024
- Indication expansion: Ongoing Ph II studies in bladder cancer and in triple-negative breast cancer
**Investment Summary**

A clinical-stage company with the goal of becoming a global ADC player

| Disruptive first-in-humans mode of action provides high efficacy and potential for unique clinical advantages |
| Clinical lead program with best-in-class potential for indication with high medical need |
| Increased efficacy against certain aggressive tumors based on biomarker |
| Validated by international high-quality partnerships |
| Strategic partnership for Asia, fastest growing pharmaceutical market |

High value potential with growing ATAC pipeline and attractive ADC environment
Q & A